Vermillion's Aspira Labs Secures Expanded Medi-Cal Coverage for OVA1

NEW YORK (GenomeWeb) – Vermillion said yesterday that its Aspira Labs subsidiary has won out-of-state provider status with Medi-Cal, California's Medicaid program, for its OVA1 ovarian cancer test.

The status gives the company access to more than 12 million Medi-Cal beneficiaries, representing roughly one-third of the covered lives in California, Vermillion said.